Comparison of Postoperative Anti-nausea and Vomiting Effect Between Glycopyrronium and Ondansetron

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

480 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-21

Study Completion Date

2023-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To compare the anti-nausea and vomiting effect between glycopyrronium and ondansetron for patients receiving elective surgery under general anesthesia. Based on this study the investigators intend to explore the feasibility of using glycopyrronium to prevent postoperative nausea and vomiting.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Glycopyrronium in Combination With Tropisetron in Anti-postoperative Nausea and Vomiting

NCT05331651

Postoperative Nausea and Vomiting

COMPLETED PHASE4

Effects of Ondansetron Dose and Timing on Post-operative Nausea and Vomiting

NCT03297021

Post-operative Nausea and Vomiting

COMPLETED PHASE4

Study Of An NK-1 Anti-Emetic Medication For The Prevention Of Post-Operative Nausea And Vomiting In Female Patients

NCT00600990

Postoperative Nausea and Vomiting Nausea and Vomiting, Postoperative

COMPLETED PHASE2

Association of 5-HT3 Receptor Gene Polymorphism With the Efficiency of Ondansetron for Postoperative Nausea and Vomiting

NCT01657786

Post Operative Nausea and Vomiting

COMPLETED NA

Efficacy of Three Antiemetics in Preventing Nausea and Vomiting

NCT05533281

Nausea and Vomiting

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postoperative Nausea and Vomiting

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Glycopyrronium

Glycopyrronium (0.2mg) was intravenously given at the ending of the surgery.

Group Type EXPERIMENTAL

Glycopyrronium

Intervention Type DRUG

Glycopyrronium (0.2mg) was intravenously given at the ending of the surgery.

Ondansetron

Ondansetron (4mg) was intravenously given at the ending of the surgery.

Group Type ACTIVE_COMPARATOR

Ondansetron

Intervention Type DRUG

Glycopyrronium (4mg) was intravenously given at the ending of the surgery.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Glycopyrronium

Glycopyrronium (0.2mg) was intravenously given at the ending of the surgery.

Intervention Type DRUG

Ondansetron

Glycopyrronium (4mg) was intravenously given at the ending of the surgery.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* American Society of Anesthesiologists classification I-III
* Receive general anesthesia
* Voluntarily receive postoperative intravenous controlled analgesia

Exclusion Criteria

* Puerpera or lactation women
* Allergy or existing contraindication to glycopyrronium and ondansetron
* Participate in other clinical drug trials within three months
* Can not follow with the study procedure

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No